Healios K.K. (HLOSF) Stock Price, News & Analysis

Company Overview

Healios K.K. is a Japan-based biotechnology company specializing in the development and commercialization of regenerative medicine and cell therapy products. Since its establishment in 2015, the firm has focused on harnessing autologous and allogeneic cell sources to address unmet medical needs in neurology and ophthalmology. Headquartered in Tokyo with a research facility in Tsukuba, Healios operates under Japan’s Pharmaceutical and Medical Device Act, holding manufacturing and marketing authorizations for its pipeline candidates.

One of Healios’s lead products, Stemirac, is an autologous bone marrow-derived mesenchymal stem cell therapy designed to promote repair in acute spinal cord injury. The company has also advanced an induced pluripotent stem cell (iPSC)-derived retinal pigment epithelial cell therapy targeting dry age-related macular degeneration. Both programs have progressed through early-stage clinical trials in Japan, with plans to seek broader regulatory approvals and strategic partnerships for global development.

In addition to its internal R&D efforts, Healios collaborates with academic institutions and research consortia in Japan to optimize manufacturing processes and ensure rigorous safety standards. The company is exploring opportunities to expand its regenerative medicine platform into Europe and North America, leveraging its expertise in autologous cell processing and iPSC technology. Healios remains led by a management team experienced in biopharmaceutical development and regulatory affairs, positioning the firm as a pioneer in Japan’s regenerative medicine industry.

Key Stats

• Today's Range: $3.44 to $3.44
• 50-Day Range: $2.25 to $3.44
• 52-Week Range: $0.96 to $3.44
• Volume: N/A
• Average Volume: 1,230 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Healios K.K. Stock Analysis - MarketRank™

Healios K.K. scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Healios K.K..

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Healios K.K. is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Healios K.K. is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Healios K.K. has a short interest ratio ("days to cover") of 857, which indicates bearish sentiment.

Change versus previous month

Short interest in Healios K.K. has recently increased by 873.86%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Healios K.K. does not currently pay a dividend.

Dividend Growth

Healios K.K. does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Healios K.K. has a short interest ratio ("days to cover") of 857, which indicates bearish sentiment.

Change versus previous month

Short interest in Healios K.K. has recently increased by 873.86%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Healios K.K. has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Healios K.K. this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Healios K.K. insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 20.34% of the stock of Healios K.K. is held by institutions.

HLOSF Stock Analysis - Frequently Asked Questions

How have HLOSF shares performed this year?

Healios K.K.'s stock was trading at $1.35 at the beginning of 2025. Since then, HLOSF shares have increased by 154.4% and is now trading at $3.4350.

How do I buy shares of Healios K.K.?

Shares of HLOSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/22/2025
• Next Earnings (Estimated): 8/12/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HLOSF
• CIK: N/A
• Web: healios.co.jp
• Phone: 81357778308
• Fax: N/A
• Employees: 64
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A